TY - JOUR
T1 - Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest
AU - Guha, Avirup
AU - Buck, Benjamin
AU - Biersmith, Michael
AU - Arora, Sameer
AU - Yildiz, Vedat
AU - Wei, Lai
AU - Awan, Farrukh
AU - Woyach, Jennifer
AU - Lopez-Mattei, Juan
AU - Plana-Gomez, Juan Carlos
AU - Oliveira, Guilherme H.
AU - Fradley, Michael G.
AU - Addison, Daniel
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Awan has received research funding from Innate Pharma , and Pharmacyclics , and provided consulting services to Gilead Sciences, Pharmacyclics, Inc, Janssen, Abbvie, Sunesis, AstraZeneca, Genentech, and Novartis Oncology, and served on the speakers bureau of Abbvie and AstraZeneca, and was supported in-part by NCI grant number R35-CA197734 . Dr Woyach received research funding from Abbvie , Pharmacyclics , Janssen , Acerta , Loxo , Karyopharm , and Morphosys , and has consulted for Janssen and Pharmacyclics, and was supported by NCI K23-CA178183 and R01-CA197870 . Dr. Oliveira receives honoraria from Abbott , Novartis and Abiomed none. Dr. Addison is supported by NCI grant number K12-CA133250 . None of the authors above and all other authors have no relationships relevant to the contents of this paper.
Publisher Copyright:
© 2019
PY - 2019/9
Y1 - 2019/9
N2 - Aim: The objective of this study was to determine whether survival and post-arrest procedural utilization following in-hospital cardiac arrest (IHCA) differ in patients with and without comorbid cancer. Methods: We retrospectively reviewed all adult (age ≥18 years old) hospital admissions complicated by IHCA from 2003 to 2014 using the National Inpatient Sample (NIS) dataset. Utilizing propensity score matching using age, gender, race, insurance, all hospital level variables, HCUP mortality score, diabetes, hypertension and cardiopulmonary resuscitation use, rates of survival to hospital discharge and post-arrest procedural utilization were compared. Results: From 2003 to 2014, there were a total of 1,893,768 hospitalizations complicated by IHCA, of which 112,926 occurred in patients with history of cancer. In a propensity matched cohort from 2012 to 2014, those with cancer were less likely to survive the hospitalization (31% vs. 46%, p < 0.0001). Following an IHCA, rates of procedural utilization in patients with cancer were significantly less when compared to those without a concurrent malignancy: coronary angiography (4.0% vs. 13.0%), percutaneous coronary intervention (2.2% and 8.0%), targeted temperature management (0.8% vs. 6.0%); p < 0.0001 for all comparisons. This patient population was less likely to have acute coronary syndrome (12.6% vs. 27.0%) or congestive heart failure (24.5% vs. 38.2%); p < 0.0001 for both comparisons. Survival improved in both groups over the study period (p < 0.0001). Conclusions: Patients with a history of cancer who sustain IHCA are less likely to receive post-arrest procedures and survive to hospital discharge. Given the expected rise in the rates of cancer survivorship, these findings highlight the need for broader application of potentially life-saving interventions to lower risk cancer patients who have sustained a cardiac arrest.
AB - Aim: The objective of this study was to determine whether survival and post-arrest procedural utilization following in-hospital cardiac arrest (IHCA) differ in patients with and without comorbid cancer. Methods: We retrospectively reviewed all adult (age ≥18 years old) hospital admissions complicated by IHCA from 2003 to 2014 using the National Inpatient Sample (NIS) dataset. Utilizing propensity score matching using age, gender, race, insurance, all hospital level variables, HCUP mortality score, diabetes, hypertension and cardiopulmonary resuscitation use, rates of survival to hospital discharge and post-arrest procedural utilization were compared. Results: From 2003 to 2014, there were a total of 1,893,768 hospitalizations complicated by IHCA, of which 112,926 occurred in patients with history of cancer. In a propensity matched cohort from 2012 to 2014, those with cancer were less likely to survive the hospitalization (31% vs. 46%, p < 0.0001). Following an IHCA, rates of procedural utilization in patients with cancer were significantly less when compared to those without a concurrent malignancy: coronary angiography (4.0% vs. 13.0%), percutaneous coronary intervention (2.2% and 8.0%), targeted temperature management (0.8% vs. 6.0%); p < 0.0001 for all comparisons. This patient population was less likely to have acute coronary syndrome (12.6% vs. 27.0%) or congestive heart failure (24.5% vs. 38.2%); p < 0.0001 for both comparisons. Survival improved in both groups over the study period (p < 0.0001). Conclusions: Patients with a history of cancer who sustain IHCA are less likely to receive post-arrest procedures and survive to hospital discharge. Given the expected rise in the rates of cancer survivorship, these findings highlight the need for broader application of potentially life-saving interventions to lower risk cancer patients who have sustained a cardiac arrest.
KW - Cancer
KW - Cardio-oncology
KW - Cardiovascular disease
KW - In-hospital cardiac arrest
UR - http://www.scopus.com/inward/record.url?scp=85069548390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069548390&partnerID=8YFLogxK
U2 - 10.1016/j.resuscitation.2019.07.005
DO - 10.1016/j.resuscitation.2019.07.005
M3 - Article
C2 - 31310845
AN - SCOPUS:85069548390
SN - 0300-9572
VL - 142
SP - 30
EP - 37
JO - Resuscitation
JF - Resuscitation
ER -